Telix Pharmaceuticals completed the acquisition of the therapeutic assets and biologics technology platform of ImaginAb for $230m.

Telix Pharmaceuticals, a biopharmaceutical company specializing in radiopharmaceuticals, completed the acquisition of the therapeutic assets and biologics technology platform of ImaginAb, antibody engineering company, for $230m. “The innovative radiotherapeutic technology platform is designed to optimize radiopharmaceutical therapies with targeting agents that are more selective and better match the pharmacology and radiobiology of a given radionuclide. The protein engineering and discovery team is excited to join Telix and further unlock the future potential of this platform and theranostic candidates,” Anna M. Wu, ImaginAb Co-Founder and Board Member.